MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson and Turning Point Therapeutics announce...
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and...
MD Anderson, Invectys and CTMC announce strategic...
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture...
MD Anderson Research Highlights for June 15, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
Androgen receptor signaling contributes to targeted therapy...
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers...
Estimating tumor-specific total mRNA level predicts cancer...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA...
MD Anderson Research Highlights: EHA 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
Genetic study offers new insights into DCIS biology,...
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson...
MD Anderson researchers present encouraging results of...
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show...
Studies reveal new insights into gut microbiome impact on...
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
MD Anderson researchers present cellular therapy advances...
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances...
Immunotherapy before surgery associated with improved...
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...
ASCO honors Eduardo Bruera, M.D., with Walther Cancer...
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received...
Ibrutinib with chemoimmunotherapy improved progression-free...
ABSTRACT LBA7502
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved...
MD Anderson and Resilience launch joint venture to...
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the...
MD Anderson Research Highlights for June 1, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...